English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Mechanisms of Disease: inherited demyelinating neuropathies - from basic to clinical research

Nave, K.-A., Sereda, M. W., & Ehrenreich, H. (2007). Mechanisms of Disease: inherited demyelinating neuropathies - from basic to clinical research. Nature Clinical Practice Neurology, 3(8), 453-464. doi:10.1038/ncpneuro0583.

Item is

Files

show Files
hide Files
:
Nave.pdf (Publisher version), 384KB
 
File Permalink:
-
Name:
Nave.pdf
Description:
-
OA-Status:
Visibility:
Restricted ( Max Planck Society (every institute); )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Nave, Klaus-Armin1, Author           
Sereda, Michael W.2, Author           
Ehrenreich, Hannelore3, Author           
Affiliations:
1Neurogenetics, Max Planck Institute of Experimental Medicine, Max Planck Society, ou_2173664              
2Molecular and translational neurology, Neurogenetics, Max Planck Institute of Experimental Medicine, Max Planck Society, ou_2173667              
3Clinical neuroscience, Max Planck Institute of Experimental Medicine, Max Planck Society, ou_2173651              

Content

show
hide
Free keywords: Charcot-Marie-Tooth disease; CMT1; demyelinating neuropathies
 Abstract: The hereditary motor and sensory neuropathies (also known as Charcot–Marie–Tooth disease or CMT) are characterized by a length-dependent loss of axonal integrity in the PNS, which leads to progressive muscle weakness and sensory deficits. The 'demyelinating' neuropathies (CMT disease types 1 and 4) are genetically heterogeneous, but their common feature is that the primary defect perturbs myelination. As we discuss in this Review, several new genes associated with CMT1 and CMT4 have recently been identified. The emerging view is that a range of different subcellular defects in Schwann cells can cause axonal loss, which represents the final common pathway of all CMT disease and is independent of demyelination. We propose that Schwann cells provide a first line of axonal neuroprotection. A better understanding of axon–glia interactions should open the way to therapeutic interventions for demyelinating neuropathies. Transgenic animal models have become essential for dissecting CMT disease mechanisms and exploring novel therapies.

Details

show
hide
Language(s): eng - English
 Dates: 2007-08
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: DOI: 10.1038/ncpneuro0583
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Nature Clinical Practice Neurology
  Other : Nat. Clin. Pract. Neurol.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: London : Nature Pub. Group
Pages: - Volume / Issue: 3 (8) Sequence Number: - Start / End Page: 453 - 464 Identifier: ISSN: 1745-834X
CoNE: https://pure.mpg.de/cone/journals/resource/1000000000025830